Abstract Body

Fc modified bNAbs are being developed for prophylactic and therapeutic treatment of HIV. Extended half-life and reduced immunogenicity modifications have proven effective, but attempts to improve bNAb efficacy by enhancing affinity for Fcg Receptors alone have not worked in SHIV-challenged macaques. In this model, ablating FcgR binding reduced protection, but the role of complement appeared limited. We hypothesized improving bNAb Fc-mediated complement activity and increasing affinity for FcgR would strengthen protection.

We developed 10 Fc variant bNAbs with site mutations designed to increase CDC activity, C1q binding, and FcgR affinity and evaluated each for binding to FcgRs, C1q and infected cells plus functional CDC, ADCC and ADCP activity. MPER targeting 10E8v4 that weakly neutralizes SHIVSF162P3 (IC50 30 mg/ml) and mediated Complement activity in vitro, but does not mediate ADCC was selected for macaque studies. Protection was evaluated with a single high dose intrarectal SHIVSF162P3 challenge 3 days after 5 mg/kg mAb infusion. Groups of 6 macaques received either unmodified 10E8v4, 10E8v4-LALA (Complement/FcgR dual knockout), 10E8v4-EFTAE, (>2-fold enhanced Complement deposition, viral lysis, and CDC, increased affinity for FcgRs with no ADCC or increased ADCP), or a control mAb. Blood draws monitored viremia, mAb kinetics, and neutralizing titers.

Unexpectedly, mean plasma viral loads (PVL) were elevated in the EFTAE group compared to unmodified 10E8v4 (P<0.0001) and LALA groups (P=0.0070). Viremia was starkly increased in multiple lymphoid and gut tissues in the EFTAE group, over unmodified 10E8v4 (P<0.0001), LALA (P=0.0270), and control (P<0.0001) groups. EFTAE mutations led to lower serum concentrations and neutralizing titers at challenge and reduced serum half-life. Higher doses of 10 and 20 mg/kg EFTAE or unmodified mAb led to comparable PVL, suggesting neutralizing titers may mitigate effects of increased complement. Mechanistic studies show splenocytes treated with sub-neutralizing EFTAE increased infection over controls dependent on the presence of monocyte derived DCs.

Our studies imply enhancing CDC in vitro may not predict in vivo function and supports evidence that increased affinity for FcgRs may not enhance protection. Implications of complement opsonization of HIV inhibiting effector cell function warrant further study. Importantly, consequences seen here of modulating complement in HIV infection may forewarn clinical safety and therapeutic trials with modified Fc bNAbs.